Monoclonal antibodies and immunotherapy are potent cancer treatments, but preventing treatment resistance to these therapies is challenging. Monoclonal antibodies fail to engage T cells for sustained antitumor immunity, and immunotherapy does not account for antigen variation across malignant cells. Bispecific antibodies offer a solution by bolstering T cell action against cancer cells and simultaneously targeting distinct antigens. In this webinar, George Weiner will discuss combining anticancer monoclonal and bispecific antibodies to enhance T cell help, and Mohamed-Reda Benmebarek will delve into using adaptable, bispecific antibodies to address antigen variability while ensuring sustained clinical efficacy.
Topics to be covered
- Exploiting the synergistic power of bispecific and monoclonal antibodies
- Developing bispecific antibodies for modular and controllable cancer therapy
Tuesday, February 6th, 2023 | 2:30 PM - 4:00 PM Eastern Time
This webinar will be available to view live and on demand.
George Weiner, MD
University of Iowa
Mohamed-Reda Benmebarek, PhD
National Cancer Institute